These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31134194)

  • 61. Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.
    Ratcliffe E; Thomas RJ; Williams DJ
    Br Med Bull; 2011; 100():137-55. PubMed ID: 21852279
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Navani A; Manchikanti L; Albers SL; Latchaw RE; Sanapati J; Kaye AD; Atluri S; Jordan S; Gupta A; Cedeno D; Vallejo A; Fellows B; Knezevic NN; Pappolla M; Diwan S; Trescot AM; Soin A; Kaye AM; Aydin SM; Calodney AK; Candido KD; Bakshi S; Benyamin RM; Vallejo R; Watanabe A; Beall D; Stitik TP; Foye PM; Helander EM; Hirsch JA
    Pain Physician; 2019 Jan; 22(1S):S1-S74. PubMed ID: 30717500
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase IV Studies: Some Insights, Clarifications, and Issues.
    Cesana BM; Biganzoli EM
    Curr Clin Pharmacol; 2018; 13(1):14-20. PubMed ID: 29651962
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regenerative Medicine Therapies for Rare Diseases.
    Lapteva L; Vatsan R; Purohit-Sheth T
    Transl Sci Rare Dis; 2018 Dec; 3(3-4):121-132. PubMed ID: 30613470
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Designing regenerative biomaterial therapies for the clinic.
    Pashuck ET; Stevens MM
    Sci Transl Med; 2012 Nov; 4(160):160sr4. PubMed ID: 23152328
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regulatory challenges for autologous tissue engineered products on their way from bench to bedside in Europe.
    Ram-Liebig G; Bednarz J; Stuerzebecher B; Fahlenkamp D; Barbagli G; Romano G; Balsmeyer U; Spiegeler ME; Liebig S; Knispel H
    Adv Drug Deliv Rev; 2015 Mar; 82-83():181-91. PubMed ID: 25446139
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Control Systems Engineering in Continuous Pharmaceutical Manufacturing May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-839. PubMed ID: 28756845
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership.
    Johnson PC; Bertram TA; Carty NR; Hellman KB; Tawil BJ; Van Dyke M
    Tissue Eng Part A; 2014 Jun; 20(11-12):1565-82. PubMed ID: 24665855
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Supervision, administration and standard research related to tissue engineered medical products].
    Xi TF; Chen L; Zhao P
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products.
    Martin I; Smith T; Wendt D
    Trends Biotechnol; 2009 Sep; 27(9):495-502. PubMed ID: 19651453
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do.
    Ribitsch I; Baptista PM; Lange-Consiglio A; Melotti L; Patruno M; Jenner F; Schnabl-Feichter E; Dutton LC; Connolly DJ; van Steenbeek FG; Dudhia J; Penning LC
    Front Bioeng Biotechnol; 2020; 8():972. PubMed ID: 32903631
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ethical hurdles for translational research.
    Sugarman J; McKenna WG
    Radiat Res; 2003 Jul; 160(1):1-4. PubMed ID: 12816517
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.
    Carvalho M; Sepodes B; Martins AP
    Front Med (Lausanne); 2017; 4():182. PubMed ID: 29124055
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.
    Scavone C; di Mauro G; Mascolo A; Berrino L; Rossi F; Capuano A
    Front Pharmacol; 2019; 10():111. PubMed ID: 30814951
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics.
    Lysaght MJ; Jaklenec A; Deweerd E
    Tissue Eng Part A; 2008 Feb; 14(2):305-15. PubMed ID: 18333783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.